SLC5A2 and type 2 diabetes mellitus: To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, and sodium‐glucose transport protein‐2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD).